{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:43:44Z","timestamp":1773431024097,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Guidelines from the National Institutes of Health support the use of balanced crystalloid solutions such as Normosol-R (Hospira, Lake Forest, IL) for patients with coronavirus disease 2019 (COVID-19). However, their clinical utility is hindered by a lack of Y-site compatibility data that is essential for use in patients with limited intravenous access. The objective of this study was to determine the physical compatibility of selected intensive care unit medications with Normosol-R.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study involved laboratory simulation of Y-site compatibility. Medications tested included amiodarone, caspofungin, dexmedetomidine, dobutamine, dopamine, epinephrine, levofloxacin, norepinephrine, pantoprazole, phenylephrine, piperacillin\/tazobactam, vancomycin, and vasopressin. Tests performed were visual assessment with Tyndall light, turbidity measurement, and pH assessment. Tests were performed immediately after mixing (with the exception of turbidity testing) and after 1 hour and 4 hours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Incompatibility was defined as observation of haze, gas, particulate, or color change or admixture turbidity above 0.3 or above 0.5 nephelometric turbidity unit (NTU), depending on whether the baseline turbidity was less than or greater than 0.5 NTU, respectively. Analysis of solubility and compatibility based on change from baseline to admixture pH in relation to the reported \u2212log of the acid dissociation constant (pKa) was performed. There was no evidence of visual incompatibility for any of the admixtures when mixed with Normosol-R. Turbidity exceeded the defined threshold with pantoprazole, phenylephrine, and highly concentrated norepinephrine. Pantoprazole was the only test medication with a significant pH change when compared to its pKa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Normosol-R is compatible for Y-site administration with all tested medications except for pantoprazole, phenylephrine, and highly concentrated norepinephrine, allowing for potential increased use in patients with COVID-19.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab329","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T10:31:05Z","timestamp":1628937065000},"page":"e27-e33","source":"Crossref","is-referenced-by-count":4,"title":["Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration"],"prefix":"10.1093","volume":"79","author":[{"given":"Amanda A","family":"Holyk","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mount Nittany Medical Center, State College, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra H","family":"Lindner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mount Nittany Medical Center, State College, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott E","family":"Lindner","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology and the Huck Center for Malaria Research, Pennsylvania State University, University Park, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian W","family":"Shippert","sequence":"additional","affiliation":[{"name":"Critical Care Services, Mount Nittany Medical Center, State College, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"2021121515420269400_CIT0001","author":"National Institutes of Health","year":"2020"},{"key":"2021121515420269400_CIT0002","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1711586","article-title":"Balanced crystalloids versus saline in noncritically ill adults","volume":"378","author":"Self","year":"2018","journal-title":"N Engl J Med"},{"key":"2021121515420269400_CIT0003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1711584","article-title":"Balanced crystalloids vs saline in critically ill adults","volume":"378","author":"Semler","year":"2018","journal-title":"N Engl J Med"},{"key":"2021121515420269400_CIT0004","volume-title":"Package insert","author":"Normosol-R","year":"2009"},{"key":"2021121515420269400_CIT0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21019\/9781582122960","volume-title":"Trissel\u2019s Stability of Compounded Formulations","author":"Trissel","year":"2018","edition":"6"},{"key":"2021121515420269400_CIT0006","volume-title":"Clinical Pharmacology powered by Clinical Key [proprietary data]","author":"Normosol-R [IV compatibility report]","year":"2019"},{"key":"2021121515420269400_CIT0007","first-page":"939","article-title":"Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets","volume":"34","author":"Allen","year":"1977","journal-title":"Am J Hosp Pharm."},{"key":"2021121515420269400_CIT0008","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/ajhp\/56.14.1458","article-title":"Compatibility of levofloxacin with 34 medications during simulated Y-site administration","volume":"56","author":"Saltsman","year":"1999","journal-title":"Am J Health-Syst Pharm."},{"key":"2021121515420269400_CIT0009","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/CCM.0b013e3181e8adcc","article-title":"Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units","volume":"38","author":"Kanji","year":"2010","journal-title":"Crit Care Med."},{"key":"2021121515420269400_CIT0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1310\/hpj5005-376","article-title":"Simulated Y-site compatibility of vancomycin and piperacillin-tazobactam","volume":"50","author":"Wade","year":"2015","journal-title":"Hosp Pharm."},{"key":"2021121515420269400_CIT0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12937-016-0149-x","article-title":"Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugs","volume":"15","author":"Staven","year":"2016","journal-title":"Nutr J."},{"key":"2021121515420269400_CIT0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/014860719902300267","article-title":"Compatibility of medications with 3-in-1 parenteral nutrition admixtures","volume":"23","author":"Trissel","year":"1999","journal-title":"J Parenter Enteral Nutr"},{"key":"2021121515420269400_CIT0013","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1093\/ajhp\/53.21.2611","article-title":"Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs","volume":"53","author":"Veltri","year":"1996","journal-title":"Am J Health-Syst Pharm"},{"key":"2021121515420269400_CIT0014","first-page":"90","article-title":"Physical compatibility of pantoprazole with selected medications during simulated Y-site administration","volume":"57","author":"Walker","year":"2004","journal-title":"Can J Hosp Pharm"},{"key":"2021121515420269400_CIT0015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2146\/ajhp140165","article-title":"Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration","volume":"72","author":"Foushee","year":"2015","journal-title":"Am J Health-Syst Pharm."},{"key":"2021121515420269400_CIT0016","first-page":"1716","article-title":"Turbidimetric assessment of the compatibility of Taxol with selected other drugs during simulated Y-site injection","volume":"49","author":"Trissel","year":"1992","journal-title":"Am J Hosp Pharm."},{"key":"2021121515420269400_CIT0017","volume-title":"TN400 Portable Turbidity Meter Instruction Manual","year":"2008"},{"key":"2021121515420269400_CIT0018","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2146\/ajhp090505","article-title":"Physical compatibility of 4% sodium citrate with selected antimicrobial agents","volume":"67","author":"Dotson","year":"2010","journal-title":"Am J Health-Syst Pharm."},{"key":"2021121515420269400_CIT0019","first-page":"87","volume-title":"Handbook on Injectable Drugs","year":"2018","edition":"20"},{"key":"2021121515420269400_CIT0020","first-page":"1469","article-title":"pKa and CLogP values for some drugs and pKa values for miscellaneous organic acids and bases","volume-title":"Foye\u2019s Principles of Medicinal Chemistry","author":"Lemke","year":"2013","edition":"7"},{"key":"2021121515420269400_CIT0021","first-page":"200","volume-title":"Medications and Mothers\u2019 Milk","author":"Hale","year":"2012","edition":"15"},{"key":"2021121515420269400_CIT0022","volume-title":"PubChem Compound Database","author":"Dexmedetomidine","year":"2018"},{"key":"2021121515420269400_CIT0023","volume-title":"PubChem Compound Database","author":"Levofloxacin","year":"2018"},{"key":"2021121515420269400_CIT0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/31.suppl_A.39","article-title":"The chemistry, pharmacokinetics, and tissue distribution of piperacillin\/tazobactam","volume":"31","author":"Sorgel","year":"1993","journal-title":"J Antimicrob Chemother."},{"key":"2021121515420269400_CIT0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/TCRM.S2564","article-title":"Zosyn (piperacillin\/tazobactam) reformulation: expanded compatibility and coadministration with lactated Ringer\u2019s solutions and selected aminoglycosides","volume":"4","author":"Desai","year":"2008","journal-title":"Ther Clin Risk Manag."},{"key":"2021121515420269400_CIT0026","volume-title":"Package insert","author":"Pantoprazole","year":"2012"},{"key":"2021121515420269400_CIT0027","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2146\/ajhp170839","article-title":"Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration","volume":"75","author":"Asempa","year":"2018","journal-title":"Am J Health-Syst Pharm."},{"key":"2021121515420269400_CIT0028","first-page":"78","article-title":"Evaluation of a simple method for visual detection of microprecipitates in blends of parenteral drug solutions using a focused (Tyndall) light beam","volume":"14","author":"Veggeland","year":"2013","journal-title":"Int J Pharm Compd."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab329\/40076590\/zxab329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/1\/e27\/41772126\/zxab329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/1\/e27\/41772126\/zxab329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T15:42:39Z","timestamp":1639582959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/1\/e27\/6352367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,14]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab329","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,14]]}}}